209 filings
Page 9 of 11
8-K
kfzeazrqxr0np
19 Jul 18
Other Events
6:59am
8-K
7ocpfeez7uihv3v
13 Jul 18
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome
9:22pm
EFFECT
rg2u9f0sx3tni
20 Jun 18
Notice of effectiveness
12:15am
8-K
p4wis4cisq4
11 Jun 18
Submission of Matters to a Vote of Security Holders
4:06pm
S-3
9ogn8j9iw7d8c
1 Jun 18
Shelf registration
5:14pm
8-K
8it1b amahc1
8 May 18
Results of Operations and Financial Condition
5:22pm
DEFA14A
bwi xkptr
24 Apr 18
Additional proxy soliciting materials
12:00am
DEF 14A
pm4hhv2jv5w7 qrx
24 Apr 18
Definitive proxy
12:00am
CT ORDER
gco8cgla
19 Apr 18
Confidential treatment order
12:00am
S-8
uayqxyw06fh9f8gz5l
29 Mar 18
Registration of securities for employees
12:00am
10-K
zcite1863xa4o4c7
29 Mar 18
Annual report
12:00am
8-K
p1iiq0krubzi2
29 Mar 18
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial
12:00am
8-K
c8fq ymrjcfi
24 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
54rrpn
11 Dec 17
Ovid Therapeutics AnnouncesTAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
12:00am
8-K
clds0
4 Dec 17
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase
12:00am
8-K
640g 6ga9qw
9 Nov 17
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress
12:00am
8-K
d7nod7l
16 Oct 17
Ovid Therapeutics Announces Positive Preclinical OV101 Data
12:00am
8-K
lqmesbuqz9p zup
10 Oct 17
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome
12:00am